Hydroxamic acid derivatives of mycophenolic acid inhibit histone deacetylase at the cellular level

Daniela I. Batovska, Dong Hoon Kim, Shinya Mitsuhashi, Yoon Sun Cho, Ho Jeong Kwon, Makoto Ubukata

Research output: Contribution to journalArticle

11 Citations (Scopus)


Mycophenolic acid (MPA, 1), an inhibitor of IMP-dehydrogenase (IMPDH) and a latent PPARγ agonist, is used as an effective immunosuppressant for clinical transplantation and recently entered clinical trials in advanced multiple myeloma patients. On the other hand, suberoylanilide hydroxamic acid (SAHA), a non-specific histone deacetylase (HDAC) inhibitor, has been approved for treating cutaneous T-cell lymphoma. MPA seemed to bear a cap, a linker, and a weak metal-binding site as a latent inhibitor of HDAC. Therefore, the hydroxamic acid derivatives of mycophenolic acid having an effective metal-binding site, mycophenolic hydroxamic acid (MPHA, 2), 7-O-acetyl mycophenolic acid (7-O-Ac MPHA, 3), and 7-O-lauroyl mycophenolic hydroxamic acid (7-O-L MPHA, 4) were designed and synthesized. All these compounds inhibited histone deacetylase with IC50 values of 1, 0.9 and 0.5 μM, and cell proliferation at concentrations of 2, 1.5 and 1 μM, respectively.

Original languageEnglish
Pages (from-to)2623-2631
Number of pages9
JournalBioscience, Biotechnology and Biochemistry
Issue number10
Publication statusPublished - 2008 Nov 5

All Science Journal Classification (ASJC) codes

  • Biotechnology
  • Analytical Chemistry
  • Biochemistry
  • Applied Microbiology and Biotechnology
  • Molecular Biology
  • Organic Chemistry

Fingerprint Dive into the research topics of 'Hydroxamic acid derivatives of mycophenolic acid inhibit histone deacetylase at the cellular level'. Together they form a unique fingerprint.

  • Cite this